Near-infrared (NIR)-tagged antibodies against EGFR have shown promise by improving tumor-to-background signal compared to existing methods, but this approach suffers from production and purification issues as well as the need for creating species-specific analogs [10, 14–16]. Here, EGFR is linked to neoplasm.